<?xml version='1.0' encoding='utf-8'?>
<document id="17686907"><sentence text="Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human."><entity charOffset="87-196" id="DDI-PubMed.17686907.s1.e0" text="(+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid" /></sentence><sentence text="The role of transporters in the disposition of (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid (CP-671,305), an orally active inhibitor of phosphodiesterase-4, was examined"><entity charOffset="47-156" id="DDI-PubMed.17686907.s2.e0" text="(+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid" /><entity charOffset="158-168" id="DDI-PubMed.17686907.s2.e1" text="CP-671,305" /><pair ddi="false" e1="DDI-PubMed.17686907.s2.e0" e2="DDI-PubMed.17686907.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17686907.s2.e0" e2="DDI-PubMed.17686907.s2.e1" /></sentence><sentence text=" In bile duct-exteriorized rats, a 7" /><sentence text="4-fold decrease in the half-life of CP-671,305 was observed, implicating enterohepatic recirculation" /><sentence text=" Statistically significant differences in CP-671,305 pharmacokinetics (clearance and area under the curve) were discernible in cyclosporin A- or rifampicin-pretreated rats"><entity charOffset="127-141" id="DDI-PubMed.17686907.s5.e0" text="cyclosporin A-" /><entity charOffset="145-155" id="DDI-PubMed.17686907.s5.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.17686907.s5.e0" e2="DDI-PubMed.17686907.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17686907.s5.e0" e2="DDI-PubMed.17686907.s5.e1" /></sentence><sentence text=" Considering that cyclosporin A and rifampicin inhibit multiple uptake/efflux transporters, the interactions of CP-671,305 with major human hepatic drug transporters, multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP), and organic anion-transporting polypeptide (OATPs) were evaluated in vitro"><entity charOffset="18-31" id="DDI-PubMed.17686907.s6.e0" text="cyclosporin A" /><entity charOffset="36-46" id="DDI-PubMed.17686907.s6.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.17686907.s6.e0" e2="DDI-PubMed.17686907.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17686907.s6.e0" e2="DDI-PubMed.17686907.s6.e1" /></sentence><sentence text=" CP-671,305 was identified as a substrate of MRP2 and BCRP, but not MDR1" /><sentence text=" CP-671,305 was a substrate of human OATP2B1 with a high affinity (Km = 4 microM) but not a substrate for human OATP1B1 or OATP1B3" /><sentence text=" Consistent with these results, examination of hepatobiliary transport of CP-671,305 in hepatocytes indicated active uptake followed by efflux into bile canaliculi" /><sentence text=" Upon examination as a substrate for major rat hepatic Oatps, CP-671,305 displayed high affinity (Km = 12 microM) for Oatp1a4" /><sentence text=" The role of rat Mrp2 in the biliary excretion was also examined in Mrp2-deficient rats" /><sentence text=" The observations that CP-671,305 pharmacokinetics were largely unaltered suggested that compromised biliary clearance of CP-671,305 was compensated by increased urinary clearance" /><sentence text=" Overall, these studies suggest that hepatic transporters play an important role in the disposition and clearance of CP-671,305 in rat and human, and as such, these studies should aid in the design of clinical drug-drug interaction studies" /><sentence text="" /></document>